briefglance.com
Cure8 news brief
Why This Matters
Fibrosis and strictures (fibrostenotic disease) are important unmet problems in Crohn’s disease with limited medical options. An investigational drug that targets PDE4 locally could potentially offer a new approach if later trials show benefit and acceptable tolerability.
Who Should Pay Attention
Patients with fibrostenotic Crohn’s disease or those interested in new anti-fibrotic/anti-inflammatory therapies, clinicians treating IBD, and researchers working on drug development for fibrotic complications.
Study Snapshot
Story typeBusiness news
Evidence typePhase 1 clinical trial
Source depthFull source text
What To Know
Palisade Bio presented on PALI-2108, a locally bioactivated PDE4 inhibitor prodrug, highlighting Phase 1a and Phase 1b results and plans to advance to Phase 2 studies in ulcerative colitis and fibrostenotic Crohn’s disease.
The talk emphasized unmet needs in fibrostenotic Crohn’s disease (fibrosis and strictures) and the company’s strategy to improve PDE4 pharmacology and tolerability via a prodrug platform.
PALI-2108 is described as investigational; the article reports early-stage clinical progress (Phase 1 trials completed with positive signals) but does not provide detailed efficacy or safety data. No treatment recommendations or specific trial outcomes are given in the source text.
If you’re tracking emerging treatments for fibrotic complications of IBD, this is a development to watch as PALI-2108 moves toward Phase 2 testing. For clinical decisions or personal treatment changes, discuss with your care team and consider that Phase 2 studies will be needed to better define benefits and risks.
Keep In Mind
This coverage summarizes a company presentation at a scientific symposium and mentions Phase 1 results and plans for Phase 2. Early positive signals in Phase 1 do not guarantee later success; detailed trial data, peer-reviewed publications, and regulatory review will be needed to judge safety and effectiveness.
The article is a market/business-focused summary rather than a full clinical report.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationbriefglance.com
Indexed viaGoogle News
Source typeBusiness news
PublishedJun 9, 2026, 4:22 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...
Palisade Bio Stock: A Unique MoA Targeting The UC And Crohn's Disease Markets (PALI)
an investigational oral drug (PALI-2108) being developed specifically for UC and Crohn’s disease, reporting favorable Phase 1 safety and early activity and noting upcoming Phase 2 readouts. For people following new...
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.